---
layout: post
title: " FDA Approves First New Pain Medication in Over Two Decades"
date: '2025-01-31T04:58:00.000-08:00'
author: Hoakam
tags:
- FDA Approves First New Pain Medication in 25 years
modified_time: '2025-01-31T04:58:48.044-08:00'
thumbnail: https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgd9epinigdUjleZUBBEGWvbR1Q3yGgVa9IMNSDVzvMRrGZ3_P2t0AwjOht4KE6kCP7F20tTonzzM2nZaO-iYzu20-mGms4fa8_hOIaC-kjzkY5y3eI7DXQEAzUZkUOADmmFd5C3z-UFZUWufKBvsJdrQzwS3PcHieom_GKU5IFqOwC9on7A_tBeZZvp7B4/s72-c/journavx.png
blogger_id: tag:blogger.com,1999:blog-6807069963721972602.post-3435204648747883527
blogger_orig_url: https://globalpulsereport.blogspot.com/2025/01/fda-approves-first-new-pain-medication.html
---

<h1 style="text-align: left;">&nbsp;<strong>FDA Approves First New Pain Medication in Over Two Decades</strong></h1><p></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgd9epinigdUjleZUBBEGWvbR1Q3yGgVa9IMNSDVzvMRrGZ3_P2t0AwjOht4KE6kCP7F20tTonzzM2nZaO-iYzu20-mGms4fa8_hOIaC-kjzkY5y3eI7DXQEAzUZkUOADmmFd5C3z-UFZUWufKBvsJdrQzwS3PcHieom_GKU5IFqOwC9on7A_tBeZZvp7B4/s871/journavx.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="640" data-original-width="871" height="235" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgd9epinigdUjleZUBBEGWvbR1Q3yGgVa9IMNSDVzvMRrGZ3_P2t0AwjOht4KE6kCP7F20tTonzzM2nZaO-iYzu20-mGms4fa8_hOIaC-kjzkY5y3eI7DXQEAzUZkUOADmmFd5C3z-UFZUWufKBvsJdrQzwS3PcHieom_GKU5IFqOwC9on7A_tBeZZvp7B4/s320/journavx.png" width="320" /></a></div><br /><strong><script type="text/javascript">
	atOptions = {
		'key' : '06de7730e1d363e031b408c27e40c384',
		'format' : 'iframe',
		'height' : 90,
		'width' : 728,
		'params' : {}
	};
</script>
<script type="text/javascript" src="//www.highperformanceformat.com/06de7730e1d363e031b408c27e40c384/invoke.js"></script></strong><p></p><p>The U.S. Food and Drug Administration (FDA) has officially approved a groundbreaking pain medication, marking the first new type to receive approval in more than 20 years.</p><p>This newly authorized drug, called suzetrigine, is a prescription medication available in 50-milligram doses, taken every 12 hours following an initial higher dose. It will be marketed under the brand name Journavx.</p><p>Dr. Jacqueline Corrigan-Curay, acting director of the FDA’s Center for Drug Evaluation and Research, emphasized the importance of this approval. “The introduction of a non-opioid pain reliever for acute pain provides an alternative to opioids and helps minimize associated risks,” she stated. The FDA’s decision to expedite the drug’s development highlights its commitment to offering safer pain management solutions.</p><h3>A New Approach to Pain Management</h3><p>Pain-relief medications, also known as analgesics, are among the most frequently prescribed drugs in hospitals, according to government health reports.</p><p>Each year, approximately 80 million Americans receive prescriptions for medications to manage moderate to severe pain. Research conducted by Vertex Pharmaceuticals, the company behind suzetrigine, indicates that about half of these prescriptions involve opioids, which carry a risk of addiction and dependence.</p><p>Suzetrigine is the first pain medication to receive FDA approval since Celebrex, a Cox-2 inhibitor classified as a nonsteroidal anti-inflammatory drug (NSAID), which was introduced in 1998.</p><p>Pain perception involves multiple parts of the body, explains Dr. Sergio Bergese, an anesthesiologist at Stony Brook University’s Renaissance School of Medicine. When tissue is damaged, nerve cells send electrical signals to the brain, which interprets these signals as pain.</p><p>Unlike opioid medications, which work by altering how the brain perceives pain, suzetrigine prevents pain-signaling nerves from sending signals in the first place.</p><p>“This medication disrupts the pain pathway so that, although the injury remains, the brain does not register the pain,” Bergese explained.</p><p>An important distinction is that suzetrigine does not produce the euphoric effects often associated with opioids, reducing the likelihood of addiction or dependency.</p><h3>Inspired by a Rare Genetic Trait</h3><p>The development of this drug was inspired by a remarkable genetic anomaly discovered in a family in Pakistan. Members of this family lacked a specific gene that enables pain signals to be transmitted through the skin, allowing them to walk barefoot over hot coals without experiencing pain.</p><p>“They could sense heat and touch, but their pain nerves didn’t function the same way,” said Stuart Arbuckle, Chief Operating Officer of Vertex Pharmaceuticals. “Otherwise, they were completely normal.”</p><p><script type="text/javascript">
	atOptions = {
		'key' : '06de7730e1d363e031b408c27e40c384',
		'format' : 'iframe',
		'height' : 90,
		'width' : 728,
		'params' : {}
	};
</script>
<script type="text/javascript" src="//www.highperformanceformat.com/06de7730e1d363e031b408c27e40c384/invoke.js"></script></p><p>It took researchers 25 years to figure out how to translate this biological trait into a pain treatment.</p><p>According to Dr. Stephen Waxman, director of the Center for Neuroscience and Regeneration Research at Yale School of Medicine, nerve cells communicate through a system similar to Morse code, using electrical impulses controlled by tiny molecular batteries called sodium channels.</p><p>Suzetrigine functions by blocking a specific sodium channel that transmits only pain-related signals.</p><h3>A Step Toward the Future of Pain Treatment</h3><p>Developing a drug that targets a single sodium channel has been a challenging process, with many unsuccessful attempts along the way. However, Waxman believes the approval of suzetrigine is a significant breakthrough that could pave the way for even more effective medications in the future.</p><p>“This approval confirms that a sodium-channel blocker can successfully reduce pain in humans,” Waxman explained. “It opens the door for a new generation of even better pain treatments.”</p><p>The medication is taken in two doses: an initial 100-milligram dose, followed by 50 milligrams every 12 hours.</p><p>However, experts caution that this drug may not be suitable for all patients or all types of pain.</p><h3>Clinical Trials and Effectiveness</h3><p>In two clinical trials involving nearly 600 patients, suzetrigine effectively managed post-surgical pain following abdominal and foot procedures, outperforming a placebo. Participants reported pain relief similar to that provided by Vicodin, which contains the opioid hydrocodone combined with acetaminophen. However, because the trials were not designed to directly compare suzetrigine and Vicodin, researchers cannot determine which medication is more effective.</p><p>Patients initially rated their pain at an average of seven on a scale from 0 to 10. Those who took suzetrigine reported a reduction of approximately 3.5 points, meaning the drug cut their pain in half rather than eliminating it completely.</p><p>In another study focusing on chronic pain caused by sciatica, suzetrigine reduced pain by about two points—similar to results seen in the placebo group. This suggests the drug may not be as effective for chronic pain.</p><p>Vertex Pharmaceuticals, however, argues that additional research has shown suzetrigine to be beneficial for long-term pain management, including diabetic neuropathy, a condition caused by nerve damage from high blood sugar.</p><p>The sciatica study was smaller than the others, involving only around 100 participants in each group. Researchers note that placebo effects can significantly influence pain studies, making results more difficult to interpret.</p><h3>Cost and Availability</h3><p>Physicians specializing in pain management have expressed enthusiasm about the new treatment option.</p><p>“The more choices we have, the better we can tailor treatments for each patient,” said Dr. Kimberley Mauer, an anesthesiologist at Oregon Health and Science University.</p><p>However, the drug’s cost may impact its accessibility. Vertex Pharmaceuticals has set a wholesale price of $15.50 per 50-milligram pill but plans to offer financial assistance programs for eligible patients.</p><p>Insurance coverage for suzetrigine remains uncertain, and patients may face difficulties obtaining it depending on their providers’ policies.</p><p><script type="text/javascript">
	atOptions = {
		'key' : '06de7730e1d363e031b408c27e40c384',
		'format' : 'iframe',
		'height' : 90,
		'width' : 728,
		'params' : {}
	};
</script>
<script type="text/javascript" src="//www.highperformanceformat.com/06de7730e1d363e031b408c27e40c384/invoke.js"></script></p><p>“We’ll have to see how insurers respond before we know how widely available it will be,” Mauer added.</p>